New data released by LifeStance Health highlights clinically meaningful improvements in symptoms for patients suffering from treatment-resistant depression following Esketamine or transcranial magnetic stimulation (TMS) treatments. This significant finding underscores the effectiveness of these innovative therapies in addressing depression cases unresponsive to conventional antidepressants. Patients receiving these treatments at LifeStance clinics reported notable reductions in depressive symptoms, leading to enhanced overall mental health and quality of life. The study supports the growing body of evidence that Esketamine and TMS offer promising options for individuals struggling with difficult-to-treat depression. LifeStance Health continues to pave the way in mental health care by incorporating cutting-edge treatment methods backed by robust clinical data. These advances provide hope and improved outcomes for patients facing persistent depressive disorders that have historically been challenging to manage.
PR NewswireNew data shows AAA Nevada gas prices steadily falling in October 2026
October 30, 2026
New data from AAA Nevada reveals that gas prices in the state have been steadily falling throughout October 2026. This decrease offers relief to Nevada